Novo Nordisk's Data Blitz: ASCO Cancer Findings Lift Pipeline Hopes as Oral Wegovy Goes Global

Novo Nordisk fights back with promising GLP-1 cancer risk data, oral Wegovy’s first international launch, and new obesity trials, yet shares remain 46% off highs.

Novo Nordisk is pulling out all the stops to reverse a bruising year on the stock market, unveiling a wave of catalysts that stretch far beyond its core diabetes and obesity franchise. From a potential breakthrough in cancer risk reduction to the first international launch of its oral Wegovy pill, the Danish drugmaker is betting big on multiple fronts to reignite investor confidence.

The most eye-catching development comes from the ASCO 2026 congress in Chicago, where more than two dozen studies suggested that GLP-1 drugs such as semaglutide could measurably lower the risk of several cancers. One large observational study tracking 110,000 women found a 35% reduction in breast cancer risk, independent of age or body mass index. Even more striking, the data showed that metastasis risk for lung, breast, colorectal and liver cancer dropped by 38% to 50% among GLP-1 users, while overall mortality across six tumour types was roughly a third lower than in control groups. These are observational findings, not randomised controlled trials, but they have already sparked significant interest among investors.

Shares remain deep in the red despite the good news. The stock closed Thursday at €37.67, up 3.5% from the previous day's €37.65, but still 46% below the 52-week high of €70.13 set in June 2025. Year-to-date, the equity is down nearly 16%, with the relative strength index neutral at 50.6. Institutional positioning tells a mixed story: hedge fund Dodge & Cox added 19.33 million shares in the first quarter of 2026, while Goldman Sachs trimmed its stake by 5.87 million shares over the same period. The median analyst price target for the US-listed shares stands at around $57.25, well above current levels.

The pipeline is also gaining momentum beyond oncology. On 1 June, Novo Nordisk began recruiting for a phase 1 trial of its new injectable obesity candidate, NNC0113-5840, which will assess safety and pharmacokinetics. Separately, the company has entered a clinical supply agreement with Veru Inc. for the phase 2b PLATEAU study, which will test Wegovy in combination with Veru's enobosarm in older adults with obesity. Novo Nordisk is providing Wegovy free of charge and securing a right of first negotiation for any future co-development, while Veru retains global rights to enobosarm.

Oral Wegovy has now made its international debut in the United Arab Emirates, the first market outside the US to launch the pill formulation. The move, driven by local demand and strong healthcare infrastructure, is based on data from the OASIS-4 study in which consistent users lost roughly 17% of their body weight. Additional markets are expected in the second half of 2026, though the company has not named specific countries. The timing is critical: large US pharmacy benefit managers have adjusted their formularies to cover competing GLP-1 products more broadly, forcing Novo Nordisk to look abroad for growth.

Goldman Sachs analyst James Quigley responded by raising his price target on the stock from 263 to 305 Danish kroner, while maintaining a "neutral" rating. He cited the oral pill's unusually rapid uptake: 1.3 million prescriptions in its first quarter on the market, followed by another 1.1 million in the first six weeks of the second quarter. The figures, he said, strengthen Novo Nordisk's competitive position in the obesity space.

Meanwhile, Novo Nordisk's controlling shareholder, Novo Holdings, is putting fresh capital to work. The foundation committed €500 million as a founding investor in the Scaleup Europe Fund, a pan-European growth vehicle targeting technology and healthcare companies in late-stage growth, with an overall target of up to €5 billion.

All eyes are now on the first week of June. On 7 June, Novo Nordisk will hold an R&D event at which updates on next-generation candidates CagriSema and Amycretin are expected. That event runs concurrent with the American Diabetes Association's Scientific Sessions from 5 to 8 June, where further cardiometabolic data should flesh out the potential of the oral GLP-1 platform. For a stock that has lost nearly half its value from its peak, the coming days could deliver the catalysts needed to close the gap.